These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34729375)

  • 21. Induction of therapeutic levels of HbF in genome-edited primary β
    Mingoia M; Caria CA; Ye L; Asunis I; Marongiu MF; Manunza L; Sollaino MC; Wang J; Cabriolu A; Kurita R; Nakamura Y; Cucca F; Kan YW; Marini MG; Moi P
    Br J Haematol; 2021 Jan; 192(2):395-404. PubMed ID: 33216968
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
    Steinberg MH
    Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genome editing using CRISPR-Cas9 to create the HPFH genotype in HSPCs: An approach for treating sickle cell disease and β-thalassemia.
    Ye L; Wang J; Tan Y; Beyer AI; Xie F; Muench MO; Kan YW
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10661-5. PubMed ID: 27601644
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in globin research using genome-wide association studies and gene editing.
    Orkin SH
    Ann N Y Acad Sci; 2016 Mar; 1368(1):5-10. PubMed ID: 26866328
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent and uniform fetal hemoglobin induction via base editing.
    Mayuranathan T; Newby GA; Feng R; Yao Y; Mayberry KD; Lazzarotto CR; Li Y; Levine RM; Nimmagadda N; Dempsey E; Kang G; Porter SN; Doerfler PA; Zhang J; Jang Y; Chen J; Bell HW; Crossley M; Bhoopalan SV; Sharma A; Tisdale JF; Pruett-Miller SM; Cheng Y; Tsai SQ; Liu DR; Weiss MJ; Yen JS
    Nat Genet; 2023 Jul; 55(7):1210-1220. PubMed ID: 37400614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Editing a γ-globin repressor binding site restores fetal hemoglobin synthesis and corrects the sickle cell disease phenotype.
    Weber L; Frati G; Felix T; Hardouin G; Casini A; Wollenschlaeger C; Meneghini V; Masson C; De Cian A; Chalumeau A; Mavilio F; Amendola M; Andre-Schmutz I; Cereseto A; El Nemer W; Concordet JP; Giovannangeli C; Cavazzana M; Miccio A
    Sci Adv; 2020 Feb; 6(7):. PubMed ID: 32917636
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
    Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
    Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KLF1 drives the expression of fetal hemoglobin in British HPFH.
    Wienert B; Martyn GE; Kurita R; Nakamura Y; Quinlan KGR; Crossley M
    Blood; 2017 Aug; 130(6):803-807. PubMed ID: 28659276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel genetic therapeutic approaches for modulating the severity of β-thalassemia (Review).
    Amjad F; Fatima T; Fayyaz T; Khan MA; Qadeer MI
    Biomed Rep; 2020 Nov; 13(5):48. PubMed ID: 32953110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Revolutionising healing: Gene Editing's breakthrough against sickle cell disease.
    Dimitrievska M; Bansal D; Vitale M; Strouboulis J; Miccio A; Nicolaides KH; El Hoss S; Shangaris P; Jacków-Malinowska J
    Blood Rev; 2024 May; 65():101185. PubMed ID: 38493007
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical variability and molecular characterization of Hbs/Gγ (Aγδβ)0-thal and Hbs/HPFH in Indian sickle cell disease patients: AIIMS experience.
    Pandey H; Singh K; Ranjan R; Pandey SK; Sharma A; Kishor K; Seth T; Mahapatra M; Saxena R
    Hematology; 2019 Dec; 24(1):349-352. PubMed ID: 30777489
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
    Lohani N; Bhargava N; Munshi A; Ramalingam S
    J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates.
    Humbert O; Radtke S; Samuelson C; Carrillo RR; Perez AM; Reddy SS; Lux C; Pattabhi S; Schefter LE; Negre O; Lee CM; Bao G; Adair JE; Peterson CW; Rawlings DJ; Scharenberg AM; Kiem HP
    Sci Transl Med; 2019 Jul; 11(503):. PubMed ID: 31366580
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
    Mahmoud Ahmed NH; Lai MI
    Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CRISPR/Cas9-based multiplex genome editing of BCL11A and HBG efficiently induces fetal hemoglobin expression.
    Han Y; Tan X; Jin T; Zhao S; Hu L; Zhang W; Kurita R; Nakamura Y; Liu J; Li D; Zhang Z; Fang X; Huang S
    Eur J Pharmacol; 2022 Mar; 918():174788. PubMed ID: 35093321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cellular function reinstitution of offspring red blood cells cloned from the sickle cell disease patient blood post CRISPR genome editing.
    Wen J; Tao W; Hao S; Zu Y
    J Hematol Oncol; 2017 Jun; 10(1):119. PubMed ID: 28610635
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CRISPR/Cas9 for Sickle Cell Disease: Applications, Future Possibilities, and Challenges.
    Demirci S; Leonard A; Haro-Mora JJ; Uchida N; Tisdale JF
    Adv Exp Med Biol; 2019; 1144():37-52. PubMed ID: 30715679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BCL11A-targeted γ-globin gene induction by triterpenoid glycosides of Fagonia indica: A preclinical scientific validation of indigenous herb for the treatment of β-hemoglobinopathies.
    Iftikhar F; Khan MBN; Tehreem S; Kanwal N; Musharraf SG
    Bioorg Chem; 2023 Nov; 140():106768. PubMed ID: 37586133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hemoglobin genetics: recent contributions of GWAS and gene editing.
    Smith EC; Orkin SH
    Hum Mol Genet; 2016 Oct; 25(R2):R99-R105. PubMed ID: 27340226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Association between BCL11A, HSB1L-MYB, and XmnI γG-158 (C/T) gene polymorphism and hemoglobin F level in Egyptian sickle cell disease patients.
    El-Ghamrawy M; Yassa ME; Tousson AMS; El-Hady MA; Mikhaeil E; Mohamed NB; Khorshied MM
    Ann Hematol; 2020 Oct; 99(10):2279-2288. PubMed ID: 32772141
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.